Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

NCT01026233 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Disease, Hodgkin
Lymphoma, Large-Cell, Anaplastic
Lymphoma, Non-Hodgkin

Interventions

DRUG: brentuximab vedotin

Sponsor

Seagen Inc.

Collaborators

[object Object]